For molecules B and C, however, the ratios are 61 and 101, respectively, both of which exceed the 31 cutoff
Investors and patients will have to wait sometime for such products to launch, however, with Zealand Pharma's CEO and President Adam Steensberg telling CNBC that he expects Petrelintide to come to market around 2030
Finding effective treatments to promote recovery in these conditions is crucial, and one potential candidate showing promise is Dihexa
The cytotoxic effects of dimethyl sulfoxide in mouse preimplantation embryos: a mechanistic study
Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP1 and amylin analogues owenhaskins Dec 19, 2025 2 min read Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
It is frequently investigated for its cytoprotective effects and ability to support recovery across various tissue types